All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
CAT | Product Name | Target Species | Antibody Clone | Antibody Host | Receptor Construction | Vector Type | Targeting Cell Type | CAR Vector Type | Inquiry & Datasheet |
XS-0323-LX652 | Anti-CLDN18.2 VHH(X3XH283) h(ICOS-41BB-CD3ζ) CAR, pCDCAR1 Vector | Human | X3XH283 | VHH-ICOS-4-1BB-CD3ζ | Lentiviral vector | T cell | CAR-T | ||
XS-0323-LX653 | Anti-CLDN18.2 VHH(X3XH284) h(ICOS-41BB-CD3ζ) CAR, pCDCAR1 Vector | Human | X3XH284 | VHH-ICOS-4-1BB-CD3ζ | Lentiviral vector | T cell | CAR-T | ||
XS-0323-LX654 | Anti-CLDN18.2 VHH(X3XH285) h(ICOS-41BB-CD3ζ) CAR, pCDCAR1 Vector | Human | X3XH285 | VHH-ICOS-4-1BB-CD3ζ | Lentiviral vector | T cell | CAR-T | ||
XS-0323-LX655 | Anti-CLDN18.2 VHH(X3XH286) h(ICOS-41BB-CD3ζ) CAR, pCDCAR1 Vector | Human | X3XH286 | VHH-ICOS-4-1BB-CD3ζ | Lentiviral vector | T cell | CAR-T | ||
XS-0323-LX656 | Anti-CLDN18.2 VHH(X3XH287) h(ICOS-41BB-CD3ζ) CAR, pCDCAR1 Vector | Human | X3XH287 | VHH-ICOS-4-1BB-CD3ζ | Lentiviral vector | T cell | CAR-T | ||
XS-0323-LX657 | Anti-CLDN18.2 VHH(X3XH288) h(ICOS-41BB-CD3ζ) CAR, pCDCAR1 Vector | Human | X3XH288 | VHH-ICOS-4-1BB-CD3ζ | Lentiviral vector | T cell | CAR-T | ||
XS-0323-LX658 | Anti-CLDN18.2 VHH(X3XH289) h(ICOS-41BB-CD3ζ) CAR, pCDCAR1 Vector | Human | X3XH289 | VHH-ICOS-4-1BB-CD3ζ | Lentiviral vector | T cell | CAR-T | ||
XS-0323-LX1015 | Anti-CLDN18.2 VHH(X3XH277) h(CD28-OX40-CD3ζ) CAR, pCDCAR1 Vector | Human | X3XH277 | VHH-CD28-OX40-CD3ζ | Lentiviral vector | T cell | CAR-T | ||
XS-0323-LX1016 | Anti-CLDN18.2 VHH(X3XH278) h(CD28-OX40-CD3ζ) CAR, pCDCAR1 Vector | Human | X3XH278 | VHH-CD28-OX40-CD3ζ | Lentiviral vector | T cell | CAR-T | ||
XS-0323-LX1017 | Anti-CLDN18.2 VHH(X3XH279) h(CD28-OX40-CD3ζ) CAR, pCDCAR1 Vector | Human | X3XH279 | VHH-CD28-OX40-CD3ζ | Lentiviral vector | T cell | CAR-T | ||
XS-0323-LX1018 | Anti-CLDN18.2 VHH(X3XH280) h(CD28-OX40-CD3ζ) CAR, pCDCAR1 Vector | Human | X3XH280 | VHH-CD28-OX40-CD3ζ | Lentiviral vector | T cell | CAR-T | ||
XS-0323-LX1019 | Anti-CLDN18.2 VHH(X3XH281) h(CD28-OX40-CD3ζ) CAR, pCDCAR1 Vector | Human | X3XH281 | VHH-CD28-OX40-CD3ζ | Lentiviral vector | T cell | CAR-T | ||
XS-0323-LX1020 | Anti-CLDN18.2 VHH(X3XH282) h(CD28-OX40-CD3ζ) CAR, pCDCAR1 Vector | Human | X3XH282 | VHH-CD28-OX40-CD3ζ | Lentiviral vector | T cell | CAR-T | ||
XS-0323-LX1021 | Anti-CLDN18.2 VHH(X3XH283) h(CD28-OX40-CD3ζ) CAR, pCDCAR1 Vector | Human | X3XH283 | VHH-CD28-OX40-CD3ζ | Lentiviral vector | T cell | CAR-T | ||
XS-0323-LX1022 | Anti-CLDN18.2 VHH(X3XH284) h(CD28-OX40-CD3ζ) CAR, pCDCAR1 Vector | Human | X3XH284 | VHH-CD28-OX40-CD3ζ | Lentiviral vector | T cell | CAR-T | ||
XS-0323-LX1023 | Anti-CLDN18.2 VHH(X3XH285) h(CD28-OX40-CD3ζ) CAR, pCDCAR1 Vector | Human | X3XH285 | VHH-CD28-OX40-CD3ζ | Lentiviral vector | T cell | CAR-T | ||
XS-0323-LX1024 | Anti-CLDN18.2 VHH(X3XH286) h(CD28-OX40-CD3ζ) CAR, pCDCAR1 Vector | Human | X3XH286 | VHH-CD28-OX40-CD3ζ | Lentiviral vector | T cell | CAR-T | ||
XS-0323-LX1025 | Anti-CLDN18.2 VHH(X3XH287) h(CD28-OX40-CD3ζ) CAR, pCDCAR1 Vector | Human | X3XH287 | VHH-CD28-OX40-CD3ζ | Lentiviral vector | T cell | CAR-T | ||
XS-0323-LX1026 | Anti-CLDN18.2 VHH(X3XH288) h(CD28-OX40-CD3ζ) CAR, pCDCAR1 Vector | Human | X3XH288 | VHH-CD28-OX40-CD3ζ | Lentiviral vector | T cell | CAR-T | ||
XS-0323-LX1027 | Anti-CLDN18.2 VHH(X3XH289) h(CD28-OX40-CD3ζ) CAR, pCDCAR1 Vector | Human | X3XH289 | VHH-CD28-OX40-CD3ζ | Lentiviral vector | T cell | CAR-T | ||
XS-0823-LX29 | Anti-hCLDN18.2 (182511) ICD(CD28-OX40-CD3ζ) CAR-MA, pAd5f35 Vector | Human | 182511 | Adenoviral vectors |
The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders
LEARN MORE NEWSLETTERCellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.
LEARN MORE SOLUTIONSilence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.
LEARN MORE NOVEL TECHNOLOGYCanine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.
LEARN MORE SOLUTION